1. Home
  2. companies
  3. Crohn's Disease

Crohn's Disease

FDA postpones key hearing on biosimilar copy of blockbuster drug
FDA postpones key hearing on biosimilar copy of blockbuster drug
Yahoo/Reuters
FDA
biosimilars
Rensima
Remicade
JNJ
rheumatoid arthritis
Crohn's Disease
Hospira
Celltrion
Celgene Crohn's drug trial successful
Celgene Crohn's drug trial successful
Yahoo/Investors Business Daily
Celgene
Crohn's Disease
Mongersen
First Detailed Look at Celgene Crohn's Disease Pill Impresses
First Detailed Look at Celgene Crohn's Disease Pill Impresses
TheStreet.com
Celgene
Crohn's Disease
GED-0301
Was Celgene's Crohn's Disease Drug Worth The Price?
Was Celgene's Crohn's Disease Drug Worth The Price?
Investors.com
Celgene
Crohn's Disease
GED-0301
Safety Worries Over Celgene's Experimental Crohn's Drug Overblown
Safety Worries Over Celgene's Experimental Crohn's Drug Overblown
TheStreet.com
Celgene
Crohn's Disease
GED-301
New biotherapeutics drug for Crohn's to enter trials
New biotherapeutics drug for Crohn's to enter trials
Pharmaphorum
Crohn's Disease
IBS
Blautix
Thetanix
4D Pharma
Takeda’s Bowel Disease Drug Approved by U.S. Regulators
Takeda’s Bowel Disease Drug Approved by U.S. Regulators
Bloomberg
Takeda
FDA
Entyvio
vedolizumab
ulcerative colitis
Crohn's Disease
Celgene enters deal potentially worth over $2.5 billion for Nogra Pharma's Crohn's disease drug
Celgene enters deal potentially worth over $2.5 billion for Nogra Pharma's Crohn's disease drug
First Word Pharma
Celgene
Nogra Pharma
Crohn's Disease
GED-0301
Takeda gets positive CHMP opinion for Entyvio for UC and Crohn’s disease
Takeda gets positive CHMP opinion for Entyvio for UC and Crohn’s disease
The Pharma Letter
Takeda
vedolizumab
Entyvio
ulcerative colitis
Crohn's Disease
AstraZeneca, Amgen Crohn's drug runs into PhII 'logistical' snafu
AstraZeneca, Amgen Crohn's drug runs into PhII 'logistical' snafu
Fierce Biotech
Amgen
Crohn's Disease
AMG 181
AstraZeneca
Coronado's inflammatory bowel disease treatment fails mid-stage study
Coronado's inflammatory bowel disease treatment fails mid-stage study
Reuters
Coronado Biosciences
Crohn's Disease
TSO
The Impact of a Failed Crohn's Disease Trial Study
The Impact of a Failed Crohn's Disease Trial Study
Motley Fool
Crohn's Disease
Vercirnon
ChemoCentryx
GSK
GSK's Crohn's disease treatment fails in Phase III trial
GSK's Crohn's disease treatment fails in Phase III trial
Reuters
GSK
Crohn's Disease
ChemoCentryx
Vercirnon
Coronado Biosciences Reuniting Old Friends
Coronado Biosciences Reuniting Old Friends
Seeking Alpha
Coronado Biosciences
CNDO-201
CNDO-109
Crohn's Disease
Multiple Myeloma
acute myeloid leukemia
[video]AbbVie's New Crohn's Disease Drug Candidate
[video]AbbVie's New Crohn's Disease Drug Candidate
Motley Fool
AbbVie
Crohn's Disease
JAK inhibitors
Galapagos
AbbVie and Galapagos extend GLPG0634 collaboration to include Crohn's disease
AbbVie and Galapagos extend GLPG0634 collaboration to include Crohn's disease
Yahoo/Reuters
Galapagos
AbbVie
GLPG0634
Crohn's Disease
Coronado Biosciences: Provides Investors With 2 Distinct Pipelines And Significant Market Potential
Coronado Biosciences: Provides Investors With 2 Distinct Pipelines And Significant Market Potential
Seeking Alpha
Coronado Biosciences
Crohn's Disease
ulcerative colitis
multiple sclerosis
OvaMed
CNDO-109
acute myeloid leukemia
Coronado Biosciences reports Phase 1 clinical trial results for TSO in Crohn's
Coronado Biosciences reports Phase 1 clinical trial results for TSO in Crohn's
Yahoo/Fly on the Wall
Coronado Biosciences
TSO
Crohn's Disease
Abbott’s Freyman Says Humira Gained Market Share in Crohn’s, Psoriasis
Abbott’s Freyman Says Humira Gained Market Share in Crohn’s, Psoriasis
Bloomberg
Crohn's Disease
psoriasis
Abbott Laboratories
Humira
Glenmark Sells Rights to New Drug to Sanofi
Glenmark Sells Rights to New Drug to Sanofi
WSJ Online
Glenmark
Sanofi
Crohn's Disease
GBR500

Click here to subscribe to daily news headlines in your email inbox